摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(±)-2-(4-(methylsulfonyl)phenyl)piperidine

中文名称
——
中文别名
——
英文名称
(±)-2-(4-(methylsulfonyl)phenyl)piperidine
英文别名
2-(4-Methanesulfonylphenyl)piperidine;2-(4-methylsulfonylphenyl)piperidine
(±)-2-(4-(methylsulfonyl)phenyl)piperidine化学式
CAS
——
化学式
C12H17NO2S
mdl
MFCD09929368
分子量
239.338
InChiKey
ALVOZMFRAZGPGD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    54.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (±)-2-(4-(methylsulfonyl)phenyl)piperidine 、 4-(chloromethyl)-5,7-dimethyl-1-tosyl-1H-indole 在 N,N-二异丙基乙胺 作用下, 以62%的产率得到(±)-5,7-dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1-tosyl-1H-indole
    参考文献:
    名称:
    Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
    摘要:
    The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.
    DOI:
    10.1021/acs.jmedchem.9b01870
  • 作为产物:
    描述:
    1-Boc-2-哌啶酮titanium(IV) isopropylate盐酸4-二甲氨基吡啶 、 ammonium molybdate 、 双氧水三乙胺 作用下, 以 四氢呋喃1,4-二氧六环乙醇甲苯 为溶剂, 反应 3.0h, 生成 (±)-2-(4-(methylsulfonyl)phenyl)piperidine
    参考文献:
    名称:
    Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
    摘要:
    The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.
    DOI:
    10.1021/acs.jmedchem.9b01870
点击查看最新优质反应信息

文献信息

  • [EN] PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINYL-INDOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR B DU COMPLÉMENT
    申请人:NOVARTIS AG
    公开号:WO2015009616A1
    公开(公告)日:2015-01-22
    The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种公式I的化合物:(I)一种制造本发明化合物的方法,以及其作为补体替代途径抑制剂的治疗用途,特别是对因子B的抑制。本发明还提供了一种药理活性剂的组合和一种药物组合。
  • Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof
    申请人:ADAMS Christopher
    公开号:US20160152605A1
    公开(公告)日:2016-06-02
    The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种公式I的化合物:(I),一种用于制造本发明化合物的方法,并且本发明化合物具有治疗作用,可作为替代途径补体的抑制剂,特别是因子B的抑制剂。本发明还提供了一种药理活性剂的组合和一种制药组合物。
  • PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
    申请人:Novartis AG
    公开号:EP3299365A1
    公开(公告)日:2018-03-28
    The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种式 I 的化合物: 一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药理活性剂组合和药物组合物。
  • Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
    申请人:Novartis AG
    公开号:US10093663B2
    公开(公告)日:2018-10-09
    The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种式 I 的化合物: 一种制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂组合和药物组合物。
  • PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS
    申请人:Novartis AG
    公开号:EP3022192A1
    公开(公告)日:2016-05-25
查看更多